Microangiopathic Hemolytic Anemia (MAHA) with Thrombotic Microangiopathy (TMA)

Diagnostic Approach

• The presence of hemolysis markers and schistocytes should trigger immediate TMA evaluation, as the absence of abundant schistocytes does not exclude TMA due to low test sensitivity 1, 2
• Critical first-line tests to order urgently include ADAMTS13 activity level and inhibitor titer, complete blood count with platelet count, lactate dehydrogenase, direct antiglobulin test, peripheral blood smear review, creatinine, and urinalysis for hematuria/proteinuria 3, 4, 1, 2, 5

Differential Diagnosis

• The triad defining TMA consists of non-immune microangiopathic hemolysis, thrombocytopenia, and organ involvement, typically renal 5, 1, 2
• Primary considerations based on ADAMTS13 results include TTP if ADAMTS13 <10% and aHUS if ADAMTS13 >10% 3, 4, 1, 2

Management

• For TTP with ADAMTS13 activity <10%, immediately initiate therapeutic plasma exchange and administer methylprednisolone 1g IV daily for 3 days 3, 4, 6
• For aHUS with clinical consequences, begin eculizumab therapy and administer meningococcal vaccination and long-term penicillin prophylaxis 5, 2
• For Grade 2 and Grade 1 cases, consider hematology consultation, prednisone, and close monitoring 3, 4, 6

Transfusion and Monitoring

• RBC transfusion should only be done to relieve symptoms or achieve hemoglobin 7-8 g/dL in stable, non-cardiac patients 3, 4, 6
• Platelet transfusion is generally contraindicated in TTP unless life-threatening bleeding 3, 4
• Daily CBC with differential, LDH, haptoglobin, and creatinine should be monitored during the acute phase 3, 4, 1

Critical Pitfalls

• Do not delay plasma exchange while awaiting ADAMTS13 results if TTP is strongly suspected clinically, as mortality increases with delayed treatment 3, 4, 6
• Do not dismiss the diagnosis based on "rare" schistocytes alone, as low schistocyte counts can occur in early or evolving TMA 1, 2

Clinical Significance and Management of Schistocytes in Blood Smears

Definition and Clinical Significance

• The presence of schistocytes is a hallmark laboratory finding in thrombotic microangiopathic anemias, particularly thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) 7
• Schistocytes above 1% can be observed in various conditions beyond TTP/HUS, including metastatic carcinoma 8, chronic renal failure 9, and mechanical heart valves 10

Diagnostic Workup

• Initial laboratory evaluation should include complete blood count with indices, reticulocyte count, peripheral blood smear examination, lactate dehydrogenase (LDH), haptoglobin, and bilirubin levels, as well as direct antiglobulin test (DAT) to differentiate immune from non-immune causes of hemolysis 11
• Specific testing for TMA should include ADAMTS13 activity level and inhibitor titer, prothrombin time, activated partial thromboplastin time, and fibrinogen 7
• Complement testing (C3, C4, CH50) should be performed for suspected complement-mediated HUS 10

Management Algorithm

• For Grade 2 TTP/HUS, administer prednisone 0.5-1 mg/kg/day, and monitor hemoglobin levels weekly during steroid tapering 7, 8
• For Grade 3 TTP/HUS, consider hospital admission, administer prednisone 1-2 mg/kg/day, and provide RBC transfusion per guidelines (target Hgb 7-8 g/dL in stable patients) 8
• For Grade 4 TTP/HUS, initiate therapeutic plasma exchange (PEX) according to guidelines, and administer methylprednisolone 1g IV daily for 3 days 7
• For severe cases of HUS with evidence of complement activation, begin eculizumab therapy (900 mg weekly for four doses, then 1,200 mg week 5, followed by 1,200 mg every 2 weeks) 9

Monitoring Recommendations

• Monitor hemoglobin levels weekly until steroid tapering is complete, then less frequently 8
• Regularly assess platelet counts, LDH, and haptoglobin to evaluate response to therapy 7

Microangiopathic Hemolytic Anemia (MAHA) with Thrombotic Microangiopathy (TMA)

Diagnostic Considerations

• The American Society of Clinical Oncology recommends prothrombin time, activated PTT, fibrinogen to exclude DIC, and blood group and antibody screen in the diagnostic workup of TMA 12
• Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis in patients with sickle cell disease shows similar laboratory findings with rapid hemoglobin decline, and the American Society of Hematology suggests considering this diagnosis in patients with similar laboratory findings 13, 14

Management

• The American Society of Clinical Oncology recommends holding any potentially causative medications and hematology consultation in Grade 1 TMA 12
• The American Society of Clinical Oncology suggests administering prednisone 0.5–1 mg/kg/day and monitoring hemoglobin weekly during steroid tapering in Grade 2 TMA 12
• The American Society of Clinical Oncology recommends considering hospital admission based on clinical judgment, hematology consultation, and prednisone 1–2 mg/kg/day in Grade 3 TMA 12
• The American Society of Clinical Oncology suggests immediately initiating therapeutic plasma exchange (PEX) according to existing guidelines, and administering methylprednisolone 1 g IV daily for 3 days in TTP (ADAMTS13 <10%) 12

Transfusion Guidelines

• The American Society of Clinical Oncology recommends RBC transfusion only to relieve symptoms or achieve hemoglobin 7–8 g/dL in stable, non-cardiac inpatients, and not to transfuse more than the minimum necessary 12
• The American Society of Hematology suggests using extended antigen-matched red cells (C/c, E/e, K, Jk^a^/Jk^b^, Fy^a^/Fy^b^, S/s) if transfusion is required in DHTR context 13, 14

Additional Immunosuppression for Refractory Cases

• The American Society of Clinical Oncology recommends considering rituximab, intravenous immunoglobulin (IVIg), and cyclosporin A or mycophenolate mofetil as alternative agents for refractory cases 12, 13, 14

Diagnosis and Management of Thrombotic Microangiopathy (TMA)

Clinical Presentation and Diagnosis

• The European Society of Cardiology recommends blood pressure measurement and funduscopic examination to evaluate for malignant hypertension in patients with TMA, as severe blood pressure elevation with advanced retinopathy can be indicative of this condition 15
• Malignant hypertension-associated TMA typically shows only moderate thrombocytopenia and few schistocytes compared to TTP/HUS, with normal or slightly reduced ADAMTS13 activity 15
• The presence of neurological symptoms is common in TTP, according to the Centers for Disease Control and Prevention (CDC) 16

Management and Treatment

• The European Society of Cardiology suggests initiating controlled blood pressure lowering in patients with severely elevated blood pressure and retinopathy, and monitoring for TMA improvement within 24-48 hours 15
• Blood pressure lowering will improve TMA within 24-48 hours in patients with malignant hypertension, according to the European Heart Journal 15

Thrombotic Microangiopathy Diagnosis and Management

Diagnostic Criteria and Testing

• The American Society of Hematology recommends testing for complement levels, including C3, C4, and CH50, to exclude complement-mediated atypical HUS in patients with suspected TMA 17
• The presence of schistocytes >1% on peripheral smear strongly supports TMA diagnosis, but their absence does not exclude early TMA 17

Management of TTP

• The American College of Physicians recommends administering methylprednisolone 1g IV daily for 3 days, with the first dose given immediately after the first plasma exchange, in patients with TTP 17
• The International Society on Thrombosis and Haemostasis suggests continuing daily plasma exchange until the platelet count exceeds 100-150 × 10⁹/L for 2 consecutive days in patients with TTP 17

Management of Atypical HUS

• The European Medicines Agency recommends beginning eculizumab therapy urgently for atypical HUS with clinical consequences, with a dosing regimen of 900 mg weekly for four doses, 1,200 mg week 5, then 1,200 mg every 2 weeks 17
• The American Society of Nephrology suggests reviewing all medications for potential TMA triggers and discontinuing them if possible in patients with atypical HUS 17

Microangiopathic Hemolytic Anemia (MAHA) with Thrombotic Microangiopathy (TMA)

Diagnostic Criteria

• Normal ferritin levels, normal B12 and folate levels, and normal MCV can help exclude iron deficiency and megaloblastic anemia as causes of anemia in patients with MAHA/TMA, according to the Annals of Oncology 18
• The presence of normal B12 (440) and folate (12) levels, and a normal MCV (90), can make B12/folate deficiency unlikely in patients with MAHA/TMA, as stated by the Annals of Oncology 18
• Normal ferritin (120) and normal B12 and folate levels can help distinguish MAHA/TMA from other causes of anemia, such as iron deficiency or megaloblastic anemia, as reported by the Annals of Oncology 18

Differential Diagnosis

• Myelodysplastic syndrome is unlikely in patients with MAHA/TMA, given the elevated reticulocyte count and presence of schistocytes, but bone marrow examination may be needed if TMA workup is negative, according to the Annals of Oncology 18

Diagnostic Criteria for Thrombotic Microangiopathy (TMA)

Laboratory Findings

• A reticulocyte index of 1.3 suggests an appropriate bone marrow response to hemolysis, distinguishing this from hypoproliferative anemias, according to the National Comprehensive Cancer Network 19
• A normal MCV (90) with anemia points toward a normocytic process consistent with hemolysis rather than nutritional deficiencies, as noted by the National Comprehensive Cancer Network 19

Complement‑Mediated Diagnostic Markers in Pregnancy‑Associated aHUS

Laboratory Indicators of Alternative Pathway Activation

• Low‑normal serum C3 level with normal C4 level reflects activation of the alternative complement pathway, which is the hallmark laboratory feature distinguishing atypical hemolytic uremic syndrome from immune‑complex–mediated thrombotic microangiopathies. 20

Identification of Acquired Complement Dysregulation

• Detection of anti‑complement factor H antibodies serves to identify an acquired mechanism of complement dysregulation in patients with atypical hemolytic uremic syndrome. 20